Association of Receptor Activator of Nuclear Factor-κB Ligand (RANKL) and Osteoprotegerin with Secondary Hypogonadism in Egyptian Females with Beta-Thalassemia Major - Egyptian Knowledge Bank - troweb

144903

Association of Receptor Activator of Nuclear Factor-κB Ligand (RANKL) and Osteoprotegerin with Secondary Hypogonadism in Egyptian Females with Beta-Thalassemia Major

Article

Last updated: 03 Jan 2025

Overview Similar Items

Article

Correlation of β-Thalassemia Major Genotype and Bone Density in Beta-Thalassemic Patient.

Article

Estimation of Osteoprotgrin Level in B Thalassemia Children

Article

Assessment of sexual maturation in patients with β-thalassemia major receiving iron chelation therapy in Assuit University Hospital

Article

Association Between Serum Levels of Adropin and Insulin Resistance in Patients with Beta-Thalassemia Major

Article

Role of serum levels of bone alkaline phosphatase and osteocalcin in thalassemia induced osteoporosis in a cohort of Egyptian females with Beta thalassemia major.

Article

Study evaluating testosterone deficiency as a cause of anemia and reduced responsiveness to erythropoiesis-stimulating agents in men on maintenance hemodialysis

Article

Multifactorial Elements Affecting Bone Mineral Status and Growth in Children with Thalassemia Major

Article

Evaluation of sex-specific association of serum testosterone and estradiol levels with frailty in elderly Egyptian men and women

Article

OSTEOPROTEGERIN (OPG) AND SOLUBLE RECEPTOR ACTIVATOR OF NUCLEAR FACTOR KAPPA B LIGAND (S-RANKL) IN PATIENTS WITH RHEUMATOID ARTHRITIS

Article

Serum osteocalcin concentration as a biomarker of osteoporosis in Egyptian patients with chronic renal failure on regular hemodialysis